Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

University of Manchester

www.manchester.ac.uk

Latest From University of Manchester

Venture Funding Deals, June 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced April through May 2016.

BioPharmaceutical Medical Device

Tech Transfer Deals, May 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced March through April 2016.

BioPharmaceutical Medical Device

Spectromics Ltd.

Spectromics Ltd. was formed to license and commercialize technology that can detect bacterial susceptibility to drugs in only 10 minutes by detecting the underlying metabolism of pathogens. The start-up aims to incorporate it into a POC test that doctors can use to expose a patient's urine sample to eight different antibiotics, to see which can kill the bugs and which meet resistance.

Medical Device

Blueberry Therapeutics Ltd.

Blueberry Therapeutics Ltd. plans to exploit nanopolymer drug delivery technologies to create safer and more effective therapeutics to treat inflammation and infection. It will start by targeting OTC indications using nanotechnology and off-patent drugs, as this will enable its candidates to move toward the market more quickly and generate revenue.

BioPharmaceutical Platform Technologies
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register